The National Health Surveillance Agency (Anvisa) approved the registration of a new dengue vaccine. The Qdenga vaccine, produced by the company Takeda Pharma, is indicated for people between 4 and 60 years old. The application is subcutaneously in a two-dose scheme, with an interval of three months between applications.
According to Anvisa, the new vaccine is made up of four different serotypes of the virus that causes the disease, which guarantees broad protection against it. Last year, Brazil recorded more than a thousand deaths from complications of dengue in the country.
Last month, the National Technical Commission on Biosafety (CTNBio) approved the safety of the Qdenga vaccine, which was now awaiting approval from Anvisa.
Another dengue vaccine already approved in the country, Dengvaxia, can only be applied by those who have already had the disease.
The Qdenga vaccine was also evaluated by the European health agency (EMA), from which it also received approval. The granting of registration by Anvisa allows the sale of the product in the country, provided that the approved conditions are maintained. The vaccine, however, will remain subject to the monitoring of adverse events through pharmacovigilance actions under the responsibility of the company itself.
